NASDAQ:AXLA - Axcella Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.50
  • Forecasted Upside: 248.31 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$4.45
▼ -0.05 (-1.11%)
1 month | 3 months | 12 months
Get New Axcella Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXLA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.50
▲ +248.31% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Axcella Health in the last 3 months. The average price target is $15.50, with a high forecast of $25.00 and a low forecast of $9.00. The average price target represents a 248.31% upside from the last price of $4.45.
Buy
The current consensus among 8 polled investment analysts is to buy stock in Axcella Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
i
9/25/2020B. RileyInitiated CoverageBuy$14.00High
i
9/24/2020B.Riley SecuritReiterated RatingBuyLow
i
Rating by M. Mamtani at B.Riley Securit
8/27/2020WedbushReiterated RatingBuy$19.00Medium
i
Rating by Liana Moussatos at Wedbush
8/14/2020WedbushReiterated RatingBuy$19.00Medium
i
Rating by Liana Moussatos at Wedbush
8/12/2020Goldman Sachs GroupReiterated RatingBuy$9.00High
i
8/6/2020SVB LeerinkLower Price TargetOutperform$20.00 ➝ $10.00Low
i
7/30/2020Piper SandlerInitiated CoverageOverweight$25.00High
i
7/9/2020BTIG ResearchLower Price TargetBuy$28.00 ➝ $16.00High
i
5/27/2020WedbushInitiated CoverageOutperform$28.00 ➝ $28.00High
i
Rating by L. Moussatos at Wedbush
5/18/2020SVB LeerinkLower Price TargetOutperform$21.00 ➝ $20.00Medium
i
5/1/2020BTIG ResearchInitiated CoverageBuy$10.00High
i
6/3/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$21.00Low
i
Rating by G. Porges at SVB Leerink LLC
6/3/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$20.00High
i
6/2/2019Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$25.00High
i
(Data available from 10/23/2015 forward)
Axcella Health logo
Axcella Health Inc., a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States. It offers AXA1665 for use in treating overt hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic steatohepatitis; AXA2678 for use in treating muscle atrophy; and AXA4010 to target multiple biological pathways to support normal structures and functions of the blood. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.45
$4.44
$4.56

50 Day Range

MA: $4.70
$4.12
$5.07

52 Week Range

Now: $4.45
$2.25
$7.73

Volume

32,783 shs

Average Volume

189,341 shs

Market Capitalization

$162.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17